Summary
Amgen Inc. (AMGN) announced on January 30, 2026, the termination of its License and Collaboration Agreement with Kyowa Kirin Co., Ltd., originally dated June 1, 2021. This termination is set to become effective upon receiving the necessary regulatory approvals, signaling a potential shift in Amgen's strategic partnerships and pipeline development. While the specific reasons for termination and the financial implications are not detailed in this filing, investors should monitor future communications for updates on how this development might impact Amgen's ongoing research and development efforts, particularly concerning any products or technologies covered under the terminated agreement. The agreement with Kyowa Kirin, if significant, could have implications for revenue streams, cost-sharing, or market access for certain therapeutic areas.
Key Highlights
- 1Amgen Inc. entered into a Termination Agreement with Kyowa Kirin Co., Ltd.
- 2The agreement effectively terminates the License and Collaboration Agreement originally signed on June 1, 2021.
- 3The termination is contingent upon receiving regulatory approval.
- 4The filing was made on January 30, 2026.
- 5The termination date of the original agreement is specified as June 1, 2021.
- 6Exhibit 10.1, the Termination Agreement, is filed with the SEC, with certain confidential portions omitted.